196 related articles for article (PubMed ID: 26044116)
1. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.
Liu L; Bello A; Dresser MJ; Heald D; Komjathy SF; O'Mara E; Rogge M; Stoch SA; Robertson SM
J Clin Pharmacol; 2016 Feb; 56(2):143-51. PubMed ID: 26044116
[TBL] [Abstract][Full Text] [Related]
2. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.
Ke AB; Zamek-Gliszczynski MJ; Higgins JW; Hall SD
Clin Pharmacol Ther; 2014 May; 95(5):473-6. PubMed ID: 24747234
[TBL] [Abstract][Full Text] [Related]
3. Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
Luo X; Xue X; Li T; Zhang Y; Huang L; Cheng G
Curr Drug Metab; 2020; 21(13):1022-1030. PubMed ID: 33092505
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Vermeer LM; Isringhausen CD; Ogilvie BW; Buckley DB
Drug Metab Dispos; 2016 Mar; 44(3):453-9. PubMed ID: 26668209
[TBL] [Abstract][Full Text] [Related]
5. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
Greenblatt DJ; Harmatz JS
Br J Clin Pharmacol; 2015 Sep; 80(3):342-50. PubMed ID: 25923589
[TBL] [Abstract][Full Text] [Related]
6. The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.
Oo C; Chen YC
J Clin Pharmacol; 2009 Mar; 49(3):368-9; author reply 370. PubMed ID: 19246734
[No Abstract] [Full Text] [Related]
7. Liver injury associated with ketoconazole: review of the published evidence.
Greenblatt HK; Greenblatt DJ
J Clin Pharmacol; 2014 Dec; 54(12):1321-9. PubMed ID: 25216238
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam.
Toi A; Ohtani H; Tsujimoto M; Sawada Y
Int J Clin Pharmacol Ther; 2010 Jun; 48(6):356-66. PubMed ID: 20497744
[TBL] [Abstract][Full Text] [Related]
9. The effect of vehicle on corneal penetration of triturated ketoconazole and itraconazole.
Guzek JP; Roosenberg JM; Gano DL; Wessels IF
Ophthalmic Surg Lasers; 1998 Nov; 29(11):926-9. PubMed ID: 9824865
[TBL] [Abstract][Full Text] [Related]
10. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.
Greenblatt DJ; von Moltke LL; Harmatz JS; Mertzanis P; Graf JA; Durol AL; Counihan M; Roth-Schechter B; Shader RI
Clin Pharmacol Ther; 1998 Dec; 64(6):661-71. PubMed ID: 9871431
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacin.
Abou-Auda HS; Mustafa AA; Al-Humayyd MS
Biopharm Drug Dispos; 2008 Jan; 29(1):29-35. PubMed ID: 17943700
[TBL] [Abstract][Full Text] [Related]
12. Proposal of a Safe and Effective Study Design for CYP3A-Mediated Drug-Drug Interactions.
Rohr BS; Mikus G
J Clin Pharmacol; 2020 Oct; 60(10):1294-1303. PubMed ID: 32437074
[TBL] [Abstract][Full Text] [Related]
13. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.
Van Peer A; Woestenborghs R; Heykants J; Gasparini R; Gauwenbergh G
Eur J Clin Pharmacol; 1989; 36(4):423-6. PubMed ID: 2544431
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
15. The triazole antifungal agents: a review of itraconazole and fluconazole.
Bailey EM; Krakovsky DJ; Rybak MJ
Pharmacotherapy; 1990; 10(2):146-53. PubMed ID: 2161523
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral antifungals and their clinical implications.
Heykants J; Van Peer A; Lavrijsen K; Meuldermans W; Woestenborghs R; Cauwenbergh G
Br J Clin Pract Suppl; 1990 Sep; 71():50-6. PubMed ID: 1965419
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model.
Chen Y; Cabalu TD; Callegari E; Einolf H; Liu L; Parrott N; Peters SA; Schuck E; Sharma P; Tracey H; Upreti VV; Zheng M; Zhu AZX; Hall SD
CPT Pharmacometrics Syst Pharmacol; 2019 Sep; 8(9):685-695. PubMed ID: 31215774
[TBL] [Abstract][Full Text] [Related]
18. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.
Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
Pharmacotherapy; 1998; 18(2):295-301. PubMed ID: 9545149
[TBL] [Abstract][Full Text] [Related]
19. Skin kinetics of azole antifungal drugs.
Cauwenbergh G
Curr Top Med Mycol; 1992; 4():88-136. PubMed ID: 1310076
[No Abstract] [Full Text] [Related]
20. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers.
Barone JA; Koh JG; Bierman RH; Colaizzi JL; Swanson KA; Gaffar MC; Moskovitz BL; Mechlinski W; Van de Velde V
Antimicrob Agents Chemother; 1993 Apr; 37(4):778-84. PubMed ID: 8388198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
